Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
This randomized phase III trial studies how well gefitinib works in treating patients with
stage IB, II, or IIIA non-small cell lung cancer that was completely removed by surgery.
Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. It is not yet known if gefitinib may be an effective treatment in preventing tumors
from returning after they have been removed by surgery.